Provided by Tiger Trade Technology Pte. Ltd.

Oculis

28.65
-0.1200-0.42%
Post-market: 28.650.00000.00%16:10 EST
Volume:287.01K
Turnover:8.20M
Market Cap:1.66B
PE:-10.51
High:28.96
Open:28.80
Low:28.05
Close:28.77
52wk High:29.36
52wk Low:14.00
Shares:57.81M
Float Shares:44.06M
Volume Ratio:0.79
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7247
EPS(LYR):-2.3426
ROE:-92.19%
ROA:-33.35%
PB:9.80
PE(LYR):-12.23

Loading ...

Company Profile

Company Name:
Oculis
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
49
Office Location:
Bahnhofstrasse 20,Zug,Zug,Switzerland
Zip Code:
6300
Fax:
- -
Introduction:
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.